Fermentalg
ISIN: FR0011271600 | Ticker: FALG | LEI: 9695007VNRQR6V5TMN85
Country: France
As an expert in research and bioindustrial exploitation of microalgae, Fermentalg’s objective is to propose sustainable solutions and innovative products contributing to the development of healthy, natural and efficient products.
Our business : the development, production and marketing of sustainable solutions and active ingredients from microalgae for nutrition, health and the environment. Nutritional lipids, functional proteins, natural colors and innovative environmental solutions are our current and future company offerings.
2009
Served areaEurope
Headquarters4 Rue Rivière, 33500 Libourne – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 41,886,000.00 | 60,876,000.00 | 57,540,000.00 |
| Noncurrent Assets | N/A | 23,233,000.00 | 27,165,000.00 | 31,240,000.00 |
| Property Plant And Equipment | N/A | 13,175,000.00 | 12,814,000.00 | 12,582,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 9,932,000.00 | 12,636,000.00 | 14,365,000.00 |
| Investment Accounted For Using Equity Method | N/A | 0.00 | 1,542,000.00 | 3,993,000.00 |
| Deferred Tax Assets | N/A | 0.00 | 0.00 | 0.00 |
| Other Noncurrent Assets | N/A | 125,000.00 | 173,000.00 | 301,000.00 |
| Current Assets | N/A | 18,653,000.00 | 33,711,000.00 | 26,300,000.00 |
| Inventories | N/A | 2,020,000.00 | 2,907,000.00 | 6,411,000.00 |
| Current Trade Receivables | N/A | 1,243,000.00 | 1,541,000.00 | 1,344,000.00 |
| Other Current Receivables | N/A | 3,550,000.00 | 3,253,000.00 | 2,643,000.00 |
| Cash and cash equivalents | 8,024,000.00 | 11,840,000.00 | 26,010,000.00 | 15,902,000.00 |
| Equity And Liabilities | N/A | 41,886,000.00 | 60,876,000.00 | 57,540,000.00 |
| Equity | 18,569,000.00 | 20,304,000.00 | 47,002,000.00 | 41,980,000.00 |
| Issued Capital | N/A | 1,011,000.00 | 1,599,000.00 | 1,684,000.00 |
| Share Premium | N/A | 18,295,000.00 | 44,819,000.00 | 44,010,000.00 |
| Reserve Of Equity Component Of Convertible Instruments | N/A | 1,051,000.00 | 473,000.00 | 473,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 20,304,000.00 | 47,002,000.00 | 41,980,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 | 0.00 |
| Noncurrent Liabilities | N/A | 11,255,000.00 | 9,589,000.00 | 10,978,000.00 |
| Other Noncurrent Liabilities | N/A | 0.00 | 218,000.00 | 538,000.00 |
| Current Liabilities | N/A | 10,327,000.00 | 4,286,000.00 | 4,583,000.00 |
| Other Shortterm Provisions | N/A | 230,000.00 | 230,000.00 | 190,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 1,481,000.00 | 1,428,000.00 | 1,522,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | N/A | 3,519,000.00 | 2,023,000.00 | 2,040,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Interest Income On Cash And Cash Equivalents | 56,000.00 | 51,000.00 | 17,000.00 |
| Other Revenue | 1,456,000.00 | 1,149,000.00 | 1,387,000.00 |
| Revenue From Contracts With Customers | 2,205,000.00 | 5,647,000.00 | 7,648,000.00 |
| Expense From Sharebased Payment Transactions With Employees | -139,000.00 | 56,000.00 | 202,000.00 |
| Profit Loss From Operating Activities | -6,180,000.00 | -5,856,000.00 | -9,030,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | N/A | -321,000.00 | -459,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -6,878,000.00 | -6,850,000.00 | -9,874,000.00 |
| Profit Loss Attributable To Owners Of Parent | -6,878,000.00 | -6,850,000.00 | -9,874,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -6,878,000.00 | -6,850,000.00 | -9,874,000.00 |
| Adjustments For Income Tax Expense | N/A | 0.00 | 0.00 | 0.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -470,000.00 | -887,000.00 | -3,504,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -657,000.00 | -304,000.00 | 355,000.00 |
| Adjustments For Sharebased Payments | N/A | 139,000.00 | 49,000.00 | 196,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | -20,000.00 | -694,000.00 | -66,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -8,368,000.00 | -7,393,000.00 | -8,212,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -2,050,000.00 | -4,747,000.00 | -7,286,000.00 |
| Proceeds From Issuing Shares | N/A | 7,800,000.00 | 30,193,000.00 | 4,549,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 7,470,000.00 | 1,391,000.00 | 1,492,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 880,000.00 | 5,050,000.00 | 525,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 203,000.00 | 268,000.00 | 32,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 14,233,000.00 | 26,311,000.00 | 5,389,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 3,815,000.00 | 14,170,000.00 | -10,116,000.00 |
| Cash and cash equivalents | 8,024,000.00 | 11,840,000.00 | 26,010,000.00 | 15,902,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 30.06.23 | None | Other | Other | EUR 0.00 |
| 30.06.23 | None | Other | Buy | EUR 0.00 |
FR0011271600
LEI9695007VNRQR6V5TMN85
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.